MT Newswires
Exelixis Insider Sold Shares Worth $4,382,252, According to a Recent SEC Filing
📉
AI Sentiment
Negative
3/10
- Home
- EXEL
EXEL
Exelixis Inc.
as of 02-23-2026 11:56am EST
$44.02
+$0.39
+0.89%
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 11.1B | IPO Year: | 2000 |
| Target Price: | $46.60 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.78 | EPS Growth: | 57.95 |
| 52 Week Low/High: | $32.38 - $48.74 | Next Earning Date: | 05-04-2026 |
| Revenue: | $452,477,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 13.66% | Revenue Growth (next year): | 14.30% |
| P/E Ratio: | 15.69 | Index: | N/A |
| Free Cash Flow: | 875.8M | FCF Growth: | +30.42% |
AI-Powered EXEL Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 17 hours ago
AI Recommendation
hold
Model Accuracy: 71.07%
71.07%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Exelixis Inc. (EXEL)
Smith Julie
Sell
Director
EXEL Feb 18, 2026
Avg Cost/Share
$44.40
Shares
64,117
Total Value
$2,849,200.50
Owned After
20,590
Hefti Brenda
Sell
SVP and General Counsel
EXEL Feb 18, 2026
Avg Cost/Share
$44.01
Shares
18,669
Total Value
$821,622.69
Owned After
96,512
SEC Form 4
Haley Patrick J.
Sell
EVP, Commercial
EXEL Feb 17, 2026
Avg Cost/Share
$43.67
Shares
67,814
Total Value
$2,950,941.24
Owned After
446,686
Senner Christopher J.
Sell
EVP and CFO
EXEL Feb 17, 2026
Avg Cost/Share
$43.67
Shares
30,617
Total Value
$1,337,044.39
Owned After
976,092
SEC Form 4
Smith Julie
Sell
Director
EXEL Feb 17, 2026
Avg Cost/Share
$43.33
Shares
42,422
Total Value
$1,838,145.26
Owned After
20,590
SEC Form 4
Senner Christopher J.
Sell
EVP and CFO
EXEL Feb 13, 2026
Avg Cost/Share
$43.00
Shares
34,278
Total Value
$1,473,954.00
Owned After
976,092
SEC Form 4
Eckhardt Sue Gail
Sell
Director
EXEL Feb 13, 2026
Avg Cost/Share
$43.79
Shares
3,856
Total Value
$168,854.24
Owned After
17,524
SEC Form 4
Oliver Bob
Sell
Director
EXEL Feb 13, 2026
Avg Cost/Share
$43.75
Shares
30,250
Total Value
$1,325,339.48
Owned After
42,282
JOHNSON DAVID EDWARD
Buy
Director
EXEL Nov 25, 2025
Avg Cost/Share
$43.12
Shares
27,532
Total Value
$1,187,234.90
Owned After
1,553,262
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Smith Julie | EXEL | Director | Feb 18, 2026 | Sell | $44.40 | 64,117 | $2,849,200.50 | 20,590 | |
| Hefti Brenda | EXEL | SVP and General Counsel | Feb 18, 2026 | Sell | $44.01 | 18,669 | $821,622.69 | 96,512 | |
| Haley Patrick J. | EXEL | EVP, Commercial | Feb 17, 2026 | Sell | $43.67 | 67,814 | $2,950,941.24 | 446,686 | |
| Senner Christopher J. | EXEL | EVP and CFO | Feb 17, 2026 | Sell | $43.67 | 30,617 | $1,337,044.39 | 976,092 | |
| Smith Julie | EXEL | Director | Feb 17, 2026 | Sell | $43.33 | 42,422 | $1,838,145.26 | 20,590 | |
| Senner Christopher J. | EXEL | EVP and CFO | Feb 13, 2026 | Sell | $43.00 | 34,278 | $1,473,954.00 | 976,092 | |
| Eckhardt Sue Gail | EXEL | Director | Feb 13, 2026 | Sell | $43.79 | 3,856 | $168,854.24 | 17,524 | |
| Oliver Bob | EXEL | Director | Feb 13, 2026 | Sell | $43.75 | 30,250 | $1,325,339.48 | 42,282 | |
| JOHNSON DAVID EDWARD | EXEL | Director | Nov 25, 2025 | Buy | $43.12 | 27,532 | $1,187,234.90 | 1,553,262 |
Latest Exelixis Inc. News
EXEL Breaking Stock News: Dive into EXEL Ticker-Specific Updates for Smart Investing
Motley Fool
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Exelixis Insider Sold Shares Worth $4,687,346, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
4/10
Insider Monkey
Here’s What Analysts Think About Arcus Biosciences (RCUS)
➖
AI Sentiment
Neutral
4/10
MT Newswires
Exelixis Insider Sold Shares Worth $821,623, According to a Recent SEC Filing
📉
AI Sentiment
Negative
3/10
MT Newswires
Exelixis Insider Sold Shares Worth $1,325,339, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
4/10
MT Newswires
Exelixis Insider Sold Shares Worth $2,950,941, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
4/10
Compare EXEL vs Leading Stocks
See how EXEL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "EXEL Exelixis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.